FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB

FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB Share Price

DE000SF2AT27

Market Closed - Deutsche Boerse AG 01:06:55 01/06/2024 am IST
1.34 ^EUR	-14.65%

1 month	+83.56%
3 months	+272.22%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	02/06	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06	RE
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	01/06	BU
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	30/05	MT

More news

Quotes 5-day view

Date	Price	Change
31/24/31	1.34	-14.65%
30/24/30	1.57	+2.61%
29/24/29	1.53	+1.32%
28/24/28	1.51	+27.97%
27/24/27	1.18	-7.09%

Delayed Quote Deutsche Boerse AG

Last update May 01, 2024 at 01:06 am IST

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SF2AT2
ISIN	DE000SF2AT27
Date issued	07/07/2021
Strike	67.22 $
Maturity	Unlimited
Parity	1 : 1
Emission price	9.69 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	44.38 €
Lowest since issue	0.035 €
Spread	0.02 €
Spread %	1.59%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus